Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 7
Primary Industries
- Therapeutic
- Drugs
- Surgical
- Wound Care
- Medical
- Tissue
- Antibody
- Chemicals
- Delivery
- Device
- Polymer
- Supply
- Cancer
- cell therapy
- ribonucleic acid
- Diabetes Treatment
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 211863
License Grant
Licensor is the assignee of all right, title and interest in the Patent Rights, Biological Materials and Know-How from a third party.
Pursuant to the third partys permission, for the nonexclusive license, Licensor grants the worldwide, nonexclusive right and license, with the right to sublicense, in the Field under the Patent Rights to make, have made, use, lease, sell, offer for sale and import the Licensed Products and to practice the Licensed Processes; to make, have made, use, lease, sell, offer for sale, import and create Modifications of the Biological Materials; and to use Know-How, and
For the exclusive license, Licensor grants the worldwide, exclusive right and license, with the right to sublicense, in the Field to make, have made, use, lease, sell, offer for sale and import Modifications.
License Property
The licensed products include among other things, Progeny, an unmodified descendant from the Biological Materials, such as virus from virus, cell from cell, or organism from organism. Some examples include subclones of unmodified cell lines, purified or fractionated subsets of the Biological Material(s), proteins expressed by DNA/RNA supplied by Licensor, or monoclonal antibodies secreted by a hybridoma cell line.
Field of Use
The Field shall mean IN VIVO human and veterinary medical use of polymers falling within the Patent Rights, including, without limitation, tissue engineering, cell therapy, implantables, medical devices, wound sealants, prescription and non-prescription drug delivery, and contrast agents, but excluding medical disposables, surgical drapes and trays, sanitary products, barrier contraceptives, nutritional and all other diagnostic uses and transgenic plant crop production of polymers.
IPSCIO Record ID: 203293
License Grant
Licensor is the assignee of all right, title and interest in the Patent Rights, Biological Materials and Know-How from a third party.
Pursuant to the third partys permission, for the nonexclusive license, Licensor grants the worldwide, nonexclusive right and license, with the right to sublicense, in the Field under the Patent Rights to make, have made, use, lease, sell, offer for sale and import the Licensed Products and to practice the Licensed Processes; to make, have made, use, lease, sell, offer for sale, import and create Modifications of the Biological Materials; and to use Know-How, and
For the exclusive license, Licensor grants the worldwide, exclusive right and license, with the right to sublicense, in the Field to make, have made, use, lease, sell, offer for sale and import Modifications.
License Property
The licensed products include among other things, Progeny, an unmodified descendant from the Biological Materials, such as virus from virus, cell from cell, or organism from organism. Some examples include subclones of unmodified cell lines, purified or fractionated subsets of the Biological Material(s), proteins expressed by DNA/RNA supplied by Licensor, or monoclonal antibodies secreted by a hybridoma cell line.
Field of Use
The Field shall mean IN VIVO human and veterinary medical use of polymers falling within the Patent Rights, including, without limitation, tissue engineering, cell therapy, implantables, medical devices, wound sealants, prescription and non-prescription drug delivery, and contrast agents, but excluding medical disposables, surgical drapes and trays, sanitary products, barrier contraceptives, nutritional and all other diagnostic uses and transgenic plant crop production of polymers.
IPSCIO Record ID: 280945
License Grant
Licensor grants to Licensee, a subsidiary, the worldwide right and license in the Field of use to make, have made, use, lease, sell, offer for sale and import the Licensed products and to practice the Licensed processes.
License Property
First amendment identifies the property of Therapeutic Uses of Polymers and Oligomers Comprising Gamma-Hydroxybutyrate.
Licensor is a biotechnology company that develops and plans to commercialize environmentally sustainable, economically attractive alternatives to petrochemical-based plastics, fuels and chemicals.
Field of Use
The field of use shall mean in vivo human and veterinary medical use of polymers falling within the patent rights, including, without limitation, tissue engineering, implantables, medical devices, drug delivery and contrast agents, but excluding medical disposables, surgical drapes and trays, nutritional and all other diagnostic uses. and excluding transgenic plant crop production of polymers.
IPSCIO Record ID: 266751
License Grant
Licensor, non-profit health care organization, grants the worldwide right and exclusive license, with the right to grant sublicenses, under the Patent Rights to make, have made, use, lease, sell, offer for sale and import for use or resale the Licensed Products, and to practice the Licensed Processes, in the Territory for the Field.
Licensor also grants a non-exclusive license to Know-how, and a non-exclusive license to use Biological Materials in connection with licensees research and development of Licensed Products.
License Property
The patents include Reconstruction of Urological Structures with Polymeric Matrices; Achievement of Excretory Renal Function Using a Neo-Morphogenic System In Vivo; Penile Reconstruction; Ex vivo Engineered Stents for Urethral Structures; Creation of Tissue Engineered Female Productive Organs (Vagina); Augmentation of Organ Function; and, Tissue Engineered Uterus and Fallopian Tubes.
Biological Materials shall mean the specific proprietary biological materials, including Progeny and Unmodified Derivatives of those materials. Progeny shall mean an unmodified descendant from the material, such as a virus from virus, cell from a cell, or organism from an organism; Unmodified Derivatives shall mean substances created by the Licensee which constitute an unmodified functional subunit or product expressed by the original material, such as subclones of unmodified cell lines, purified or fractionated subsets of the original material, proteins expressed by DNA/RNA, or monoclonal antibodies secreted by a hybridoma cell line; and Modifications shall mean substances created by the Licensee which contain or incorporate the material.
Field of Use
Field of Use shall mean the development and commercialization of tissue engineered products for human and animal therapeutics in the subfields of genitourinary, vascular tissue, nervous tissue, trachea and other subfields when and if mutually agreed upon by the parties in writing.
IPSCIO Record ID: 260380
License Grant
For the Licensed Technology, the Licensor, of the Netherlands, grants a non-exclusive, non-transferable, right and license, with the right to grant sublicenses, under the Licensed Technology, to make, have made, use, have used, offer for sale, have offered for sale, sell, have sold, import and have imported the Products in the Territory and the Field.
For the Evaluation License, Licensor grants a nonexclusive, non-transferable, worldwide right and license, with rights to sublicense, for the Term of this Agreement, under all intellectual property rights owned or controlled by Licensor as of the Effective Date or at any time during the Term, to evaluate the Secondary Assets, and all materials and information relating thereto, including without limitation the Secondary Asset Preliminary Materials, solely for the purposes of determining whether Licensee desires to exercise the Option with respect to any such Secondary Assets.
License Property
Licensor owns certain proprietary cell lines producing biosimilar monoclonal antibodies to Trastuzumab, Bevacizumab and Rituxirnab.
Product means any antibody product, including, without limitation, fragments thereof, produced by Licensee, its Affiliates or sublicensees from the Assets.
Primary Asset means CHOBC® cell lines producing the biosimilar monoclonal antibody Trastuzumab; unmodified descendants of those cell lines; unmodified subunits, including without limitation subclones, purified or fractionated subsets thereof; and, material that contains or incorporates any of the above.
Secondary Assets means the Bevacizumab Asset and the Rituximab Asset.
Bevacizumab Asset means CHOBC® cell lines producing biosimilar monoclonal antibodies to Bevacizumab; unmodified descendants of those cell lines; unmodified subunits, including without limitation subclones, purified or fractionated subsets thereof; and, material that contains or incorporates any of the above.
Rituximab Asset means CHOBC® cell lines producing biosimilar monoclonal antibodies to Rituxhnab; unmodified descendants of those cell lines; unmodified subunits, including without limitation subclones, purified or fractionated subsets thereof; and, material that contains or incorporates any of the above.
Field of Use
The Field means any and all fields. The Licensee, following a merger, became a commercial-stage biotechnology company focused on improving patient access to important biopharmaceuticals by developing, manufacturing, and commercializing biosimilar therapeutics, or biosimilars, in targeted geographies worldwide.
Bevacizumab is a medication used to treat a number of types of cancers and a specific eye disease. For cancer it is given by slow injection into a vein and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma.
Rituximab is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B cells.
Trastuzumab is a monoclonal antibody used to treat breast cancer. Specifically it is used for breast cancer that is HER2 receptor positive.
IPSCIO Record ID: 245931
License Grant
The French Licensor grants a worldwide, exclusive license under the Licensed Materials and Licensed Know-How, with the right to grant and authorize sublicenses, to make, have made, import, have imported, use, offer for sale, sell and otherwise distribute Licensed Products, practice any method, process or procedure, or otherwise exploit, in each case, Licensed Materials and Licensed Know-How for use in the Field.
License Property
Licensed Antibody shall mean the anti-CD28 antibody named B-T3 produced by the Licensed Cell Line, and any modifications.
Licensed Cell Line shall mean the B-T3 hybridoma cell line and all progeny, clones, derivatives and modifications.
Cell line B-T3 is murine IgG2a monoclonal anti-Human CD28 Antibody.
Licensed Product shall mean beads coated with the Licensed Antibody and made with use of the Licensed Materials.
Field of Use
The Field shall mean all ex vivo uses for therapeutic purposes and research applications and purposes using or relating to the Licensed Antibody or the Licensed Product.
IPSCIO Record ID: 243427
License Grant
The University grants to the Licensee a non-exclusive, worldwide, royalty-bearing license, with the right to sublicense, under its commercial rights in the Patent Rights and Biological Materials to develop, make, have made, use, and sell Licensed Products in the Field. Licensee shall have the right to grant sublicenses.
License Property
The patents are for RNA Sequence-Specific Mediators of RNA Interference.
Licensed Product means any product that cannot be developed, manufactured, used, or sold without infringing one or more claims under the Patent Rights, or, using or incorporating some portion of one or more Biological Materials.
Biological Materials means the tangible biological materials described in the patents, as well as tangible materials that are routinely produced through use of the original materials, including, for example, any progeny derived from a cell line, monoclonal antibodies produced by hybridoma cells, DNA or RNA replicated from isolated DNA or RNA, recombinant proteins produced through use of isolated DNA or RNA, and substances routinely purified from a source material included in the original materials.
UMMC 01-36 “RNA Sequence-Specific Mediators of RNA Interference†Inventors David P. Bartel, Philip A. Sharp, Thomas Tuschl, and Philip D. Zamore
I. United States Patents and Application
USSN 60/265232 entitled “RNA Sequence-Specific Mediators of RNA Interferenceâ€
USSN 09/821832 entitled “RNA Sequence-Specific Mediators of RNA Interferenceâ€
PCT/US01/10188 entitle “RNA Sequence-Specific Mediators of RNA Interferenceâ€
Field of Use
The field of use is therapeutics limited to the narrowed fields of other Medical School license agreements; specifically, using RNAi to inhibit HCMV Immediate Early (IE) gene expression in Retinitis applications, using RNAi to inhibit mutant SOD 1 gene expression in Amytrophic Lateral Sclerosis (ALS) applications, and using RNAi to inhibit gene targets implicated in Type II Diabetes and Obesity under the rights of Medical School in any patent rights claiming those inventions.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
